NO774311L - Fremgangsmaate ved fremstilling av immunologiske materialer - Google Patents
Fremgangsmaate ved fremstilling av immunologiske materialerInfo
- Publication number
- NO774311L NO774311L NO774311A NO774311A NO774311L NO 774311 L NO774311 L NO 774311L NO 774311 A NO774311 A NO 774311A NO 774311 A NO774311 A NO 774311A NO 774311 L NO774311 L NO 774311L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- cell line
- rna
- sensitized
- immune
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000001900 immune effect Effects 0.000 title abstract description 15
- 239000000463 material Substances 0.000 title abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 229
- 239000000427 antigen Substances 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 108010074605 gamma-Globulins Proteins 0.000 claims description 39
- 241001494479 Pecora Species 0.000 claims description 28
- 241000282414 Homo sapiens Species 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 24
- 239000000385 dialysis solution Substances 0.000 claims description 24
- 210000004698 lymphocyte Anatomy 0.000 claims description 21
- 230000006698 induction Effects 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 13
- 210000002751 lymph Anatomy 0.000 claims description 10
- 239000007791 liquid phase Substances 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 241000589562 Brucella Species 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 241000700199 Cavia porcellus Species 0.000 claims description 3
- 241000700159 Rattus Species 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 229940108131 coccidioidin Drugs 0.000 claims description 2
- 229940026309 histoplasmin Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 3
- 239000002609 medium Substances 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 102000006306 Antigen Receptors Human genes 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108010083359 Antigen Receptors Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000008105 immune reaction Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- TUDXHDSCPJSDIO-UHFFFAOYSA-N 4-amino-2-hydroxybenzoic acid;sodium Chemical compound [Na].NC1=CC=C(C(O)=O)C(O)=C1 TUDXHDSCPJSDIO-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- -1 RITC Tetramethylrhodamine isothiocyanate Isomer Chemical class 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 108010088880 plasmagel Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- ZKBBQUFQDGOTBZ-UHFFFAOYSA-N sodium;1,2,3-tri(propan-2-yl)naphthalene Chemical compound [Na].C1=CC=C2C(C(C)C)=C(C(C)C)C(C(C)C)=CC2=C1 ZKBBQUFQDGOTBZ-UHFFFAOYSA-N 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB52674/76A GB1594097A (en) | 1976-12-16 | 1976-12-16 | Production of specific immune nucleic acids cell dialysates and antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO774311L true NO774311L (no) | 1978-06-19 |
Family
ID=10464835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO774311A NO774311L (no) | 1976-12-16 | 1977-12-14 | Fremgangsmaate ved fremstilling av immunologiske materialer |
Country Status (14)
Country | Link |
---|---|
US (1) | US4224404A (xx) |
JP (1) | JPS5375321A (xx) |
AU (1) | AU3151977A (xx) |
BE (1) | BE861857A (xx) |
CA (1) | CA1110988A (xx) |
DK (1) | DK557477A (xx) |
ES (1) | ES465059A1 (xx) |
FI (1) | FI773784A (xx) |
FR (1) | FR2374330A1 (xx) |
GB (1) | GB1594097A (xx) |
IE (1) | IE46215B1 (xx) |
LU (1) | LU78690A1 (xx) |
NL (1) | NL7713832A (xx) |
NO (1) | NO774311L (xx) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3364347D1 (en) * | 1982-04-09 | 1986-08-07 | Fujirebio Kk | Anti immune complex antibody and preparation thereof |
DE3245665A1 (de) * | 1982-05-04 | 1983-11-10 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung permanenter tierischer und humaner zellinien und deren verwendung |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4851510A (en) * | 1984-11-30 | 1989-07-25 | Wadley Technologies, Inc. | Monoclonal antibodies to novel melanoma-associated antigens |
US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
DE69034078T2 (de) * | 1989-03-21 | 2004-04-01 | Vical, Inc., San Diego | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
ES2113371T3 (es) * | 1989-11-16 | 1998-05-01 | Univ Duke | Transformacion de celulas epidermicas de tejidos animales con la ayuda de particulas. |
US20030186913A1 (en) * | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
NZ262582A (en) * | 1993-01-26 | 1997-10-24 | David B Weiner | Compositions and methods for delivery of genetic material |
US5981505A (en) * | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US20040087521A1 (en) * | 1993-03-18 | 2004-05-06 | Merck & Co., Inc. | Nucleic acid pharmaceuticals-influenza matrix |
JPH09500013A (ja) * | 1993-06-01 | 1997-01-07 | ライフ・テクノロジーズ・インコーポレイテッド | カチオン性脂質による遺伝子免疫 |
US6348449B1 (en) | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
US6995008B1 (en) | 1994-03-07 | 2006-02-07 | Merck & Co., Inc. | Coordinate in vivo gene expression |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1617545C2 (de) | 1967-06-19 | 1983-11-03 | Diether Prof. Dr. Bern Jachertz | Verwendung von informatorischer Ribonucleinsäure als Vaccine |
GB1443948A (en) | 1972-10-20 | 1976-07-28 | Piktor Ltd | Production of immunological material |
-
1976
- 1976-12-16 GB GB52674/76A patent/GB1594097A/en not_active Expired
-
1977
- 1977-12-14 FR FR7737742A patent/FR2374330A1/fr active Granted
- 1977-12-14 NO NO774311A patent/NO774311L/no unknown
- 1977-12-14 BE BE183460A patent/BE861857A/xx unknown
- 1977-12-14 US US05/860,451 patent/US4224404A/en not_active Expired - Lifetime
- 1977-12-14 ES ES465059A patent/ES465059A1/es not_active Expired
- 1977-12-14 AU AU31519/77A patent/AU3151977A/en active Pending
- 1977-12-14 JP JP15040677A patent/JPS5375321A/ja active Pending
- 1977-12-14 IE IE2535/77A patent/IE46215B1/en unknown
- 1977-12-14 CA CA293,032A patent/CA1110988A/en not_active Expired
- 1977-12-14 NL NL7713832A patent/NL7713832A/xx not_active Application Discontinuation
- 1977-12-14 DK DK557477A patent/DK557477A/da unknown
- 1977-12-14 FI FI773784A patent/FI773784A/fi not_active Application Discontinuation
- 1977-12-14 LU LU7778690A patent/LU78690A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK557477A (da) | 1978-06-17 |
CA1110988A (en) | 1981-10-20 |
US4224404A (en) | 1980-09-23 |
LU78690A1 (xx) | 1979-02-02 |
JPS5375321A (en) | 1978-07-04 |
FR2374330B3 (xx) | 1981-02-06 |
IE46215B1 (en) | 1983-04-06 |
BE861857A (fr) | 1978-06-14 |
AU3151977A (en) | 1979-06-21 |
IE46215L (en) | 1978-06-16 |
ES465059A1 (es) | 1978-09-01 |
GB1594097A (en) | 1981-07-30 |
NL7713832A (nl) | 1978-06-20 |
FI773784A (fi) | 1978-06-17 |
FR2374330A1 (fr) | 1978-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO774311L (no) | Fremgangsmaate ved fremstilling av immunologiske materialer | |
McGrath | Replication of mammary tumor virus in tumor cell cultures: dependence on hormone-induced cellular organization | |
Howard et al. | Characterization of the collagen synthesized by endothelial cells in culture. | |
US5866363A (en) | Method and means for sorting and identifying biological information | |
JP3502125B2 (ja) | 形質転換細胞の抽出および培養ならびにそれらに対する抗体の製造 | |
WO1994006463A1 (en) | Immortalized cells and uses therefor | |
Chee et al. | Production of melanoma-associated antigen (s) by a defined malignant melanoma cell strain grown in chemically defined medium | |
Minowada et al. | Studies of Burkitt lymphoma cells. I. Establishment of a cell line (B35M) and its characteristics | |
Merl et al. | Efficient transformation of previously activated and dividing T lymphocytes by human T cell leukemia-lymphoma virus | |
Konijn et al. | Synthesis of cyclic AMP in Dictyostelium discoideum and Polysphondylium pallidum | |
Phillips et al. | Ultrastructural distribution of cell surface antigens in avian tumor virus-infected chick embryo fibroblasts | |
Irie et al. | Relation between the tumor-specific antigen and cytological characteristics in mouse mammary tumors | |
Itoh et al. | Isoantibodies to human cancer cells in healthy recipients of cancer homotransplants | |
US4001080A (en) | Production of immunological materials | |
Hutton et al. | The isolation of colicine V and a study of its immunological properties | |
Ishimoto et al. | Presence of antibody against mouse fetal antigen in the sera from C57BL/6 mice immunized with Rauscher leukemia | |
EP0116949B1 (en) | Adult t cell leukemia associated cell strains and a method for the preparation of said strain and respective antiserum | |
Appella et al. | Biological and biochemical properties of soluble tumor-specific transplantation antigen of a simian virus 40-induced neoplasm | |
Morton et al. | Some properties of the inhibitor (s) of lymphocyte mitosis derived from Mycoplasma | |
Kong et al. | Factors affecting primary and secondary antibody production by splenic tissues | |
Svehag | In vitro secondary 19 S and 7 S antibody responses to poliovirus in membrane cultures of separated spleen cells | |
Creemers et al. | Murine mammary tumor virus protein vaccine: induction of antivirus immunity and inhibition or acceleration of growth of transplanted mammary tumors | |
US3313706A (en) | Diagnostic antigen for viral hepatitis | |
Romsdahl et al. | Immunological studies on malignant melanomas of man. | |
Labzoffsky et al. | New complement fixing antigen for serodiagnosis of gonorrhoea |